Literature DB >> 23101468

Excess mortality after curative surgery for colorectal cancer changes over time and differs for patients with colon versus rectal cancer.

Bjørn Steinar Nedrebø1, Kjetil Søreide, Morten Tandberg Eriksen, Jan Terje Kvaløy, Jon Arne Søreide, Hartwig Kørner.   

Abstract

BACKGROUND: Improved management of colorectal cancer patients has resulted in better five-year survival for rectal cancer compared with colon cancer. We compared excess mortality rates in various time intervals after surgery in patients with colon and rectal cancer.
MATERIAL AND METHODS: We analysed all patients with curative resection of colorectal cancers reported in the Cancer Registry of Norway before (1994-1996) and after (2001-2003) national treatment guidelines were introduced. Excess mortality was analysed in different postoperative time intervals within the five-year follow-up periods for patients treated in 1994-1996 vs. 2001-2003.
RESULTS: A total of 11 437 patients that underwent curative resection were included. For patients treated from 1994 to 1996, excess mortality was similar in colon and rectal cancer patients in all time intervals. For those treated from 2001 to 2003, excess mortality was significantly lower in rectal cancer patients than in colon cancer patients perioperatively (in the first 60 days: excess mortality ratio = 0.46, p = 0.007) and during the first two postoperative years (2-12 months: excess mortality ratio = 0.54, p = 0.010; 1-2 years: excess mortality ratio = 0.60, p = 0.009). Excess mortality in rectal cancer patients was significantly greater than in colon cancer patients 4-5 years postoperatively (excess mortality ratio = 2.18, p = 0.003).
CONCLUSION: Excess mortality for colon and rectal cancer changed substantially after the introduction of national treatment guidelines. Short-term excess mortality rates was higher in colon cancer compared to rectal cancer for patients treated in 2001-2003, while excess mortality rates for rectal cancer patients was significantly higher later in the follow-up period. This suggests that future research should focus on these differences of excess mortality in patients curatively treated for cancer of the colon and rectum.

Entities:  

Mesh:

Year:  2012        PMID: 23101468     DOI: 10.3109/0284186X.2012.731522

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Learning curve of endorectal ultrasonography in preoperative staging of rectal carcinoma.

Authors:  Zuo-Liang Liu; Tong Zhou; Xiao-Bo Liang; Jun-Jie Ma; Guang-Jun Zhang
Journal:  Mol Clin Oncol       Date:  2014-07-17

Review 2.  Neo-adjuvant radiotherapy in rectal cancer.

Authors:  Bengt Glimelius
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  Downregulated Tim-3 expression is responsible for the incidence and development of colorectal cancer.

Authors:  Ping Zhang; Yan Wang; Xue-Rong Liu; Shi-Ru Hong; Jian Yao
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

4.  KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection?

Authors:  Kjetil Søreide; Oddvar M Sandvik; Jon A Søreide
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

5.  Long-Term Follow-Up and Survivorship After Completing Systematic Surveillance in Stage I-III Colorectal Cancer: Who Is Still at Risk?

Authors:  T Veen; K Stormark; B S Nedrebø; M Berg; J A Søreide; H Kørner; Kjetil Søreide
Journal:  J Gastrointest Cancer       Date:  2015-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.